Dupilumab may reduce COPD exacerbations in patients regardless of emphysema status: Study
A new study published in the journal of Respiratory Medicine showed that patients with type 2 inflammation and chronic obstructive pulmonary disease (COPD), with or without investigator-reported emphysema, showed comparable levels of dupilumab effectiveness. Significantly diminished lung function and a higher chance of exacerbations which are defined by increasing cough or dyspnea, an increase in the volume or purulence of sputum, or a combination of these symptoms that is frequently linked to chronic obstructive pulmonary disease. Despite the use of inhaled drugs, exacerbations are also linked to a higher risk of mortality from any cause, a faster deterioration in lung function, and an increased risk of recurrent exacerbations.
Although COPD has long been thought to include an enhanced innate immune response, there is emerging evidence that some people with the condition have type 2 inflammation. The interleukin-4 and interleukin-13 pathways raise fractional exhaled nitric oxide (FeNO) levels and, more generally, enhance eosinophil and type 2 inflammatory cell infiltrations in the lung. In the phase 3 BOREAS study, patients with type 2 inflammation and chronic obstructive pulmonary disease experienced fewer exacerbations and better lung function when treated with dupilumab, a completely human monoclonal antibody that targets the common receptor component for interleukin-4 and interleukin-13. Thus, this study was carried out by Surya Bhatt and colleagues to evaluate clinical outcomes in BOREAS patients according to their emphysema status.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.